|
OKUYAMA Ryo
Department Ritsumeikan Asia Pacific University College of International Management Position Professor |
|
| Language | English |
| Publication Date | 2024/03 |
| Type | Research paper |
| Peer Review | Peer reviewed |
| Title | Trends in COVID-19 Vaccine Development: Vaccine Platform, Developer, and Nationality. |
| Contribution Type | Single Work |
| Journal | Vaccines |
| Journal Type | Another Country |
| Volume, Issue, Page | 12(3),pp.259 |
| Total page number | 14 |
| Authorship | Lead author,Corresponding author |
| Author and coauthor | Ryo Okuyama |
| Details | Vaccine platforms and developers involved in COVID-19 vaccine development were analyzed, elucidating the trends of vaccine platforms used, the country distribution of the developers, and differences in the profiles of developers by vaccine platforms and country. Conventional, established, and emerging vaccine platforms have been widely used and that older platforms are more advanced in clinical development. It also demonstrated the emergence of China, in addition to the U.S., while many pharmerging countries have been engaged in development. Startups have significantly contributed to the development of viral vector and RNA-based vaccines, suggesting their important role in the application of novel technologies. The major developers differ by country and region. Alliances, including international collaborations, have progressed in late clinical development. Future perspectives of pandemic vaccine development and implications for policy and corporate strategies are discussed. |
| DOI | https://doi.org/10.3390/vaccines12030259 |